30 results
8-K
EX-99.1
REPL
Replimune Group Inc
26 Mar 24
Replimune Announces Appointment of Sushil Patel to CEO and Executive Leadership Transitions
7:33am
in skin cancer and beyond.”
About Replimune
Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 with the mission to transform cancer
8-K
EX-99.1
REPL
Replimune Group Inc
8 Feb 24
Replimune Reports Fiscal Third Quarter 2024 Financial Results and Provides Corporate Update
8:05am
with the mission to transform cancer treatment by pioneering the development of a novel portfolio of oncolytic immunotherapies. Replimune’s proprietary
8-K
EX-99.1
REPL
Replimune Group Inc
8 Jan 24
Regulation FD Disclosure
8:00am
controlled pivotal study in uveal melanoma underway Plan to investigate other rare cancer opportunities (1) Unaudited es,mate
MISSION To enable tumor
8-K
EX-99.1
REPL
Replimune Group Inc
5 Dec 23
Other Events
7:19am
minutes prior to the start time.
About Replimune
Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 with the mission
8-K
EX-99.1
qeulyoldat
7 Nov 23
Replimune Reports Fiscal Second Quarter 2024 Financial Results and Provides Corporate Update
8:15am
8-K
EX-99.1
kjmv3vercrmj4sx0
19 Sep 23
Replimune Announces Appointment of Emily Hill as Chief Financial Officer
8:15am
8-K
EX-99.2
dc17d5wfpbx4v1
3 Aug 23
Replimune Reports Fiscal First Quarter 2024 Financial Results and Provides Corporate Update
8:09am
8-K
EX-99.1
pcm5a
3 Aug 23
Replimune Reports Fiscal First Quarter 2024 Financial Results and Provides Corporate Update
8:09am
8-K
EX-99.1
2z50xovfe nn0whlx
20 Jul 23
Replimune Announces Sander Slootweg will Depart from its Board of Directors
8:56am
8-K
EX-99.1
sixe0nuyn m0rl3b91
5 Jun 23
Replimune Appoints Veleka R. Peeples-Dyer to its Board of Directors
8:11am
8-K
EX-99.1
cy78vk3y
18 May 23
Replimune Reports Fiscal Fourth Quarter and Year Ended 2023 Financial Results and Provides Corporate Update
8:08am
8-K
EX-99.2
hf97rko
12 Dec 22
Replimune Announces Proposed Public Offering
5:00pm
8-K
EX-99.1
zno wbefmg2g8o
12 Dec 22
Replimune Announces Proposed Public Offering
5:00pm
8-K
EX-99.1
tizf94u
7 Dec 22
Replimune Enters into Clinical Collaboration Agreement with Roche for the Development of RP3 In Colorectal Cancer and Hepatocellular Carcinoma
7:15am
8-K
EX-99.2
chdbrcgu6qeg2xgz nn
7 Dec 22
Replimune Enters into Clinical Collaboration Agreement with Roche for the Development of RP3 In Colorectal Cancer and Hepatocellular Carcinoma
7:15am
8-K
EX-99.1
3vsz78
3 Nov 22
Replimune Reports Fiscal Second Quarter Financial Results and Provides Corporate Update
8:11am
8-K
EX-99.1
ecw bst9fh
7 Oct 22
Entry into a Material Definitive Agreement
8:20am
8-K
EX-99.1
2avt v4g979cofbtk
4 Aug 22
Replimune Reports Fiscal First Quarter Financial Results and Provides Corporate Update
8:10am